BERKELEY HEIGHTS, N.J., Sept. 13, 2024 (GLOBE NEWSWIRE) — CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases, today announced that management will be participating in a fireside chat and investor meetings at the 2024 Cantor Healthcare Conference, being held in New York, NY on September 17 – 19, 2024.
Cantor Global Healthcare Conference
Date: | Thursday, September 19, 2024 | |
Time: | 10:55AM EDT | |
Format: | Fireside Chat and 1×1 Meetings | |
Webcast: | Click Link | |
A replay of the fireside chat will also be available in the “Events and Presentations” page on the investor relations portion of the Company’s website at: www.cormedix.com
About CorMedix
CorMedix Inc. is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases. The Company is focused on commercializing its lead product DefenCath®, which was approved by the FDA on November 15, 2023. CorMedix commercially launched DefenCath in inpatient settings in April 2024 and in outpatient settings in July 2024. CorMedix also intends to develop DefenCath as a catheter lock solution for use in other patient populations. For more information visit: www.cormedix.com.
Investor Contact:
Dan Ferry
Managing Director
LifeSci Advisors
[email protected]
(617) 430-7576
- Bragar Eagel & Squire, P.C. Is Investigating Winnebago, Visa, Kaspi, and Sun Communities and Encourages Investors to Contact the Firm - October 4, 2024
- Bragar Eagel & Squire, P.C. Is Investigating iLearningEngines, Elastic, and Acadia and Encourages Investors to Contact the Firm - October 4, 2024
- VERV REMINDER – Robbins LLP Urges VERV Investors to Obtain Legal Counsel in Light of the Pending Lead Plaintiff Deadline - October 4, 2024